The current standard of care for acute myeloid leukemia (AML), which includes chemotherapy regimens such as the 7+3 regimen and stem cell transplants, may not be suitable for elderly patients, who constitute a majority of patients with AML. Alexandre Bazinet, MD, McGill University, Montreal, Canada, describes novel, lower intensity approaches towards treating AML, including 5-azacytidine and venetoclax. Dr Bazinet additionally mentions targeted inhibitors such as FLT3 and IDH1 inhibitors, as well as combinations of the aforementioned treatments to create new regimens. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.